All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F16%3AN0000035" target="_blank" >RIV/00064211:_____/16:N0000035 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/16:10327988

  • Result on the web

    <a href="https://www.ncbi.nlm.nih.gov/pubmed/27538636" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/27538636</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.jns.2016.05.059" target="_blank" >10.1016/j.jns.2016.05.059</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections

  • Original language description

    The study evaluates the clinical significance of CXCL13 (leukocyte chemoattractant synthesized in CSF) in Lyme neuroborreliosis (LNB) and other aseptic CNS infections. 244 patients with symptoms of neuroinfection and/or LNB were divided into groups: A - patients with LNB-positive antibodies in serum and CSF (96) or CSF only (14); B - patients with aseptic non-borrelial neuroinfections (82); C - negative controls (52). Group A was divided into A1-A4 according to pleocytosis in CSF and AIIgG positivity. The highest CSF CXCL13 concentrations (max. 81,287.60 pg/ml; median 1766.90 pg/ml) were in A1 (positive AI, pleocytosis) and A3 (negative AIIgG, pleocytosis; max. 7201,60 pg/ml, median 56.22 pg/ml). A2 ( positive AI without pleocytosis) and A4 (negative Al without pleocytosis) had low CXCL13 levels - A2 max. 650.50 pg/ml (median < 7.80 pg/ml); A4 max. 118.56 pg/ml (median < 7.8 pg/ml). In B the median was 28.10 pg/ml (max. 595.87 pg/ml). In C the CXCL13 concentrations were the lowest (max. 83.83 pg/ml; median < 7.80 pg/ml). The lowest cut-off was 29 pg/ml (sensitivity 90.0%, specificity 72.2%), the highest one 400 pg/ml (sensitivity 59.6%, specificity 94.0%). The group differences of serum CXCL13 were insignificant. The highest concentrations were at the beginning of the disease. In LNB CXCL13 correlates better with the CSF pleocytosis than AI positivity. (C) 2016 Elsevier B.V. All rights reserved.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FN - Epidemiology, infection diseases and clinical immunology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/NT13467" target="_blank" >NT13467: Tick-borne neuroinfection - clinical manifestations and diagnostic</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    JOURNAL OF THE NEUROLOGICAL SCIENCES

  • ISSN

    0022-510X

  • e-ISSN

  • Volume of the periodical

    368

  • Issue of the periodical within the volume

    SEP 15 2016

  • Country of publishing house

    NL - THE KINGDOM OF THE NETHERLANDS

  • Number of pages

    7

  • Pages from-to

    214-220

  • UT code for WoS article

    000382415700045

  • EID of the result in the Scopus database